Plain-English translation of NCT06073847 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world safety study of Inrebic (), a medication used to treat myelofibrosis—a bone marrow disease that affects blood cell production. Researchers want to learn how safe and how well this medication works in Korean patients who have already tried another treatment and found it wasn't working well enough or caused too many side effects. The study will follow patients over time to watch for any safety concerns.
When a medication is first approved, doctors and researchers need to keep watching how it performs in everyday patients—not just in controlled research settings. This study exists to make sure the medication is safe and working as expected for Korean patients with myelofibrosis, especially those who couldn't tolerate or benefit from their previous treatment.
You likely qualify if…
You likely don't qualify if…
You would take the medication as your doctor prescribes it, just as you normally would. Researchers will track your safety and how well the treatment is working by reviewing your medical records and checking in with you over the study period. This is not an experimental trial where you're trying something brand new—you're helping researchers learn more about a medication you're already taking by sharing your real-world experience.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
South Korea